Scotia Capital Inc. Trims Stock Position in Pfizer Inc. (NYSE:PFE)

Scotia Capital Inc. lessened its holdings in Pfizer Inc. (NYSE:PFE) by 29.2% in the 4th quarter, Holdings Channel.com reports. The firm owned 794,246 shares of the biopharmaceutical company’s stock after selling 328,203 shares during the quarter. Scotia Capital Inc.’s holdings in Pfizer were worth $21,073,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Retirement Wealth Solutions LLC purchased a new stake in shares of Pfizer during the fourth quarter worth $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer in the fourth quarter valued at $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer during the fourth quarter worth about $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer in the fourth quarter valued at about $31,000. Finally, Curio Wealth LLC acquired a new stake in Pfizer in the fourth quarter valued at about $32,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

NYSE PFE opened at $22.50 on Thursday. The stock has a market capitalization of $127.61 billion, a price-to-earnings ratio of 15.96, a PEG ratio of 0.64 and a beta of 0.67. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The business’s 50 day moving average is $25.42 and its two-hundred day moving average is $26.51. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.10 earnings per share. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.06% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. UBS Group reduced their price objective on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a report on Tuesday. Citigroup reiterated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. The Goldman Sachs Group restated a “neutral” rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a research note on Tuesday. Finally, Truist Financial reduced their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.07.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.